Naive donor NK cell repertoires associated with less leukemia relapse after allogeneic hematopoietic stem cell transplantation

Journal of Immunology

Volumn 196, Issue 3, 2016, Pages 1400-1411

  Bjorklund , Andreas T ^a,b   Clancy, Trevor ^c   Goodridge, Jodie P ^c   Beziat, Vivien ^b   Schaffer, Marie ^b   Hovig, Eivind ^c,d   Ljunggren, Hans Gustaf ^b   Ljungman, Per T ^a   Malmberg, Karl Johan ^a,b,c,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NKG2C PROTEIN; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CELL SIZE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LYMPHOCYTE FUNCTION; MOLECULAR DYNAMICS; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; THERAPY EFFECT; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; ALLOGRAFT; CHILD; CLUSTER ANALYSIS; COMPLICATION; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; LEUKEMIA; LYMPHOCYTE SUBPOPULATION; MALE; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; CHILD; CLUSTER ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LEUKEMIA; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; RECURRENCE; TISSUE DONORS; YOUNG ADULT;

EID: 84957609686     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501434     Document Type: Article

References (62)

1. Vivier, E., D. H. Raulet, A. Moretta, M. A. Caligiuri, L. Zitvogel, L. L. Lanier, W. M. Yokoyama, and S. Ugolini. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
2. Valiante, N. M., M. Uhrberg, H. G. Shilling, K. Lienert-Weidenbach, K. L. Arnett, A. D'Andrea, J. H. Phillips, L. L. Lanier, and P. Parham. 1997. Functionally and structurally distinct NK cell receptor repertoires in the pe-ripheral blood of two human donors. Immunity 7: 739-751.
3. Anfossi, N., P. André, S. Guia, C. S. Falk, S. Roetynck, C. A. Stewart, V. Breso, C. Frassati, D. Reviron, D. Middleton, et al. 2006. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25: 331-342.
4. Kim, S., J. Poursine-Laurent, S. M. Truscott, L. Lybarger, Y. J. Song, L. Yang, A. R. French, J. B. Sunwoo, S. Lemieux, T. H. Hansen, and W. M. Yokoyama. 2005. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713.
5. Sun, J. C., J. N. Beilke, and L. L. Lanier. 2010. Immune memory redefined: characterizing the longevity of natural killer cells. Immunol. Rev. 236: 83-94.
6. Sun, J. C., J. N. Beilke, and L. L. Lanier. 2009. Adaptive immune features of natural killer cells. Nature 457: 557-561.
7. Béziat, V., O. Dalgard, T. Asselah, P. Halfon, P. Bedossa, A. Boudifa, B. Hervier, I. Theodorou, M. Martinot, P. Debré, et al. 2012. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur. J. Immunol. 42: 447-457.
8. hi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 108: 14725-14732.
9. Gumá, M., A. Angulo, C. Vilches, N. Gómez-Lozano, N. Malats, and M. López-Botet. 2004. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104: 3664-3671.
10. 2/2 umbilical cord blood. J. Immunol. 192: 1471-1479.
11. Foley, B., S. Cooley, M. R. Verneris, M. Pitt, J. Curtsinger, X. Luo, S. Lopez-Vergès, L. L. Lanier, D. Weisdorf, and J. S. Miller. 2012. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119: 2665-2674.
12. Della Chiesa, M., M. Falco, M. Podestà, F. Locatelli, L. Moretta, F. Frassoni, and A. Moretta. 2012. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cyto-megalovirus? Blood 119: 399-410.
13. Béziat, V., L. L. Liu, J. A. Malmberg, M. A. Ivarsson, E. Sohlberg, A. T. Björklund, C. Retière, E. Sverremark-Ekström, J. Traherne, P. Ljungman, et al. 2013. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 121: 2678-2688.
14. Lopez-Vergès, S., J. M. Milush, S. Pandey, V. A. York, J. Arakawa-Hoyt, H. Pircher, P. J. Norris, D. F. Nixon, and L. L. Lanier. 2010. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16 + NK-cell subset. Blood 116: 3865-3874.
15. Björkström, N. K., P. Riese, F. Heuts, S. Andersson, C. Fauriat, M. A. Ivarsson, A. T. Björklund, M. Flodström-Tullberg, J. Michaëlsson, M. E. Rottenberg, et al. 2010. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116: 3853-3864.
16. Béziat, V., B. Descours, C. Parizot, P. Debré, and V. Vieillard. 2010. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One 5: e11966.
17. Leung, W. 2011. Use of NK cell activity in cure by transplant. Br. J. Haematol. 155: 14-29.
18. Cooley, S., E. Trachtenberg, T. L. Bergemann, K. Saeteurn, J. Klein, C. T. Le, S. G. Marsh, L. A. Guethlein, P. Parham, J. S. Miller, and D. J. Weisdorf. 2009. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113: 726-732.
19. Venstrom, J. M., G. Pittari, T. A. Gooley, J. H. Chewning, S. Spellman, M. Haagenson, M. M. Gallagher, M. Malkki, E. Petersdorf, B. Dupont, and K. C. Hsu. 2012. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Engl. J. Med. 367: 805-816.
20. Hsu, K. C., C. A. Keever-Taylor, A. Wilton, C. Pinto, G. Heller, K. Arkun, R. J. O'Reilly, M. M. Horowitz, and B. Dupont. 2005. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105: 4878-4884.
21. Foley, B., S. Cooley, M. R. Verneris, J. Curtsinger, X. Luo, E. K. Waller, C. Anasetti, D. Weisdorf, and J. S. Miller. 2012. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J. Immunol. 189: 5082-5088.
22. Elmaagacli, A. H., N. K. Steckel, M. Koldehoff, Y. Hegerfeldt, R. Trenschel, M. Ditschkowski, S. Christoph, T. Gromke, L. Kordelas, H. D. Ottinger, et al. 2011. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118: 1402-1412.
23. Ito, S., P. Pophali, W. Co, E. K. Koklanaris, J. Superata, G. A. Fahle, R. Childs, M. Battiwalla, and A. J. Barrett. 2013. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant. 48: 1313-1316.
24. Green, M. L., W. M. Leisenring, H. Xie, R. B. Walter, M. Mielcarek, B. M. Sandmaier, S. R. Riddell, and M. Boeckh. 2013. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122: 1316-1324.
25. Cichocki, F., S. Cooley, Z. Davis, T. E. DeFor, H. Schlums, B. Zhang, C. G. Brunstein, B. R. Blazar, J. Wagner, D. J. Diamond, et al. 2015. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia.
26. Haas, P., P. Loiseau, R. Tamouza, J. M. Cayuela, H. Moins-Teisserenc, M. Busson, G. Henry, C. S. Falk, D. Charron, G. Socié, et al. 2011. NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hema-topoietic stem cell transplantation. Blood 117: 1021-1029.
27. Vago, L., B. Forno, M. P. Sormani, R. Crocchiolo, E. Zino, S. Di Terlizzi, M. T. Lupo Stanghellini, B. Mazzi, S. K. Perna, A. Bondanza, et al. 2008. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 112: 3488-3499.
28. Giebel, S., J. Dziaczkowska, T. Czerw, J. Wojnar, M. Krawczyk-Kulis, I. Nowak, A. Holowiecka, A. Segatti, S. Kyrcz-Krzemien, P. Kusnierczyk, and J. Holowiecki. 2010. Sequential recovery of NK cell receptor repertoire after allogeneic hematopoietic SCT. Bone Marrow Transplant. 45: 1022-1030.
29. Stern, M., C. de Angelis, E. Urbani, A. Mancusi, F. Aversa, A. Velardi, and L. Ruggeri. 2010. Natural killer-cell KIR repertoire reconstitution after hap-loidentical SCT. Bone Marrow Transplant. 45: 1607-1610.
30. Shilling, H. G., K. L. McQueen, N. W. Cheng, J. A. Shizuru, R. S. Negrin, and P. Parham. 2003. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 101: 3730-3740.
31. Rowlings, P. A., D. Przepiorka, J. P. Klein, R. P. Gale, J. R. Passweg, P. J. Henslee-Downey, J. Y. Cahn, S. Calderwood, A. Gratwohl, G. Socié, et al. 1997. IBMTR Severity Index for grading acute graft-versus-host disease: ret-rospective comparison with Glucksberg grade. Br. J. Haematol. 97: 855-864.
32. Filipovich, A. H., D. Weisdorf, S. Pavletic, G. Socie, J. R. Wingard, S. J. Lee, P. Martin, J. Chien, D. Przepiorka, D. Couriel, et al. 2005. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant. 11: 945-956.
33. Avetisyan, G., J. Aschan, H. Hägglund, O. Ringdén, and P. Ljungman. 2007. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant. 40: 865-869.
34. Ljungman, P., P. Griffiths, and C. Paya. 2002. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis. 34: 1094-1097.
35. Olerup, O., and H. Zetterquist. 1992. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39: 225-235.
36. Fine, J., and R. Gray. 1999. Proportional hazard model for the sub-distribution of competing risks. J. Am. Stat. Assoc. 94: 496-509.
37. Armand, P., C. J. Gibson, C. Cutler, V. T. Ho, J. Koreth, E. P. Alyea, J. Ritz, M. L. Sorror, S. J. Lee, H. J. Deeg, et al. 2012. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 120: 905-913.
38. Sun, J. C., S. Lopez-Verges, C. C. Kim, J. L. DeRisi, and L. L. Lanier. 2011. NK cells and immune "memory". J. Immunol. 186: 1891-1897.
39. Muntasell, A., C. Vilches, A. Angulo, and M. López-Botet. 2013. Adaptive reconfiguration of the human NK-cell compartment in response to cytomega-lovirus: a different perspective of the host-pathogen interaction. Eur. J. Immunol. 43: 1133-1141.
40. Li, H., V. Pascal, M. P. Martin, M. Carrington, and S. K. Anderson. 2008. Genetic control of variegated KIR gene expression: polymorphisms of the bidirectional KIR3DL1 promoter are associated with distinct frequencies of gene expression. PLoS Genet. 4: e1000254.
41. Ljungman, P., M. Hakki, and M. Boeckh. 2011. Cytomegalovirus in hemato-poietic stem cell transplant recipients. Hematol. Oncol. Clin. North Am. 25: 151-169.
42. Mori, T., and J. Kato. 2010. Cytomegalovirus infection/disease after hemato-poietic stem cell transplantation. Int. J. Hematol. 91: 588-595.
43. Lönnqvist, B., O. Ringdèn, P. Ljungman, B. Wahren, and G. Gahrton. 1986. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br. J. Haematol. 63: 671-679.
44. Scheper, W., S. van Dorp, S. Kersting, F. Pietersma, C. Lindemans, S. Hol, S. Heijhuurs, Z. Sebestyen, C. Gründer, V. Marcu-Malina, et al. 2013. gdT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 27: 1328-1338.
45. Ljungman, P. 2013. CMV: a warrior against leukemia? Blood 122: 1101-1102.
46. Davis, Z. B., S. A. Cooley, F. Cichocki, M. Felices, R. Wangen, X. Luo, T. E. DeFor, Y. T. Bryceson, D. J. Diamond, C. Brunstein, et al. 2015. Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor He-matopoietic Cell Transplantation. Biol. Blood Marrow Transplant. 21: 1653-1662.
47. Ljungman, P., R. Brand, J. Hoek, R. de la Camara, C. Cordonnier, H. Einsele, J. Styczynski, K. N. Ward, and S. Cesaro, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. 2014. Donor cy-tomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin. Infect. Dis. 59: 473-481.
48. Brodin, P., T. Lakshmikanth, R. Mehr, M. H. Johansson, A. D. Duru, A. Achour, M. Salmon-Divon, K. Kärre, P. Höglund, and S. Johansson. 2010. Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice. PLoS One 5: 5.
49. Verheyden, S., S. Ferrone, A. Mulder, F. H. Claas, R. Schots, B. De Moerloose, Y. Benoit, and C. Demanet. 2009. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunol. Immunother. 58: 855-865.
50. Masuda, K., A. Hiraki, N. Fujii, T. Watanabe, M. Tanaka, K. Matsue, Y. Ogama, M. Ouchida, K. Shimizu, K. Ikeda, and M. Tanimoto. 2007. Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leu-kemic blasts. Cancer Sci. 98: 102-108.
51. Demanet, C., A. Mulder, V. Deneys, M. J. Worsham, P. Maes, F. H. Claas, and S. Ferrone. 2004. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 103: 3122-3130.
52. Cooley, S., F. Xiao, M. Pitt, M. Gleason, V. McCullar, T. L. Bergemann, K. L. McQueen, L. A. Guethlein, P. Parham, and J. S. Miller. 2007. A sub-population of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110: 578-586.
53. Björklund, A. T., M. Schaffer, C. Fauriat, O. Ringdén, M. Remberger, C. Hammarstedt, A. J. Barrett, P. Ljungman, H. G. Ljunggren, and K. J. Malmberg. 2010. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 115: 2686-2694.
54. Foley, B., S. Cooley, M. R. Verneris, J. Curtsinger, X. Luo, E. K. Waller, D. J. Weisdorf, and J. S. Miller. 2011. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cyto-toxic functions. Blood 118: 2784-2792.
55. Luetke-Eversloh, M., B. B. Cicek, F. Siracusa, J. T. Thom, A. Hamann, S. Frischbutter, R. Baumgrass, H. D. Chang, A. Thiel, J. Dong, and C. Romagnani. 2014. NK cells gain higher IFN-g competence during terminal differentiation. Eur. J. Immunol. 44: 2074-2084.
56. Fauriat, C., S. Andersson, A. T. Björklund, M. Carlsten, M. Schaffer, N. K. Björkström, B. C. Baumann, J. Michaëlsson, H. G. Ljunggren, and K. J. Malmberg. 2008. Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J. Immunol. 181: 6010-6019.
57. Kübler, A., J. Woiterski, K. E. Witte, H. J. Bühring, U. F. Hartwig, M. Ebinger, L. Oevermann, M. Mezger, W. Herr, P. Lang, et al. 2014. Both mature KIR+ and immature KIR-NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice. Blood 124: 3914-3923.
58. Miller, J. D., D. A. Weber, C. Ibegbu, J. Pohl, J. D. Altman, and P. E. Jensen. 2003. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J. Immunol. 171: 1369-1375.
59. Merino, A. M., S. Sabbaj, J. Easlick, P. Goepfert, R. A. Kaslow, and J. Tang. 2013. Dimorphic HLA-B signal peptides differentially influence HLA-E - And natural killer cell-mediated cytolysis of HIV-1-infected target cells. Clin. Exp. Immunol. 174: 414-423.
60. Schmidt-Hieber, M., S. Schwarck, A. Stroux, S. Ganepola, P. Reinke, E. Thiel, L. Uharek, and I. W. Blau. 2010. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int. J. Hematol. 91: 877-885.
61. Busca, A., R. Passera, M. Pini, F. Zallio, C. Dellacasa, E. Audisio, L. Giaccone, E. Maffini, C. Costa, R. Cavallo, and B. Bruno. 2015. The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors. Am. J. Hematol. 90: E117-E121.
62. Cooley, S., V. McCullar, R. Wangen, T. L. Bergemann, S. Spellman, D. J. Weisdorf, and J. S. Miller. 2005. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106: 4370-4376.